ANCA - Normal Range, Markers & Result Interpretation

The ANCA test (anti-neutrophil cytoplasmic antibodies) is a key diagnostic tool used to identify autoimmune diseases such as vasculitis. In this article we cover the reference ranges and parameters relevant to this test and explain how to interpret the results. Understanding these aspects matters for both clinicians and patients to effectively monitor and manage autoimmune disease.

How to interpret your results

An ANCA result is reported in two layers: the immunofluorescence pattern (positive or negative, and if positive, c-ANCA or p-ANCA) and — when the screen is positive — the antibody level measured against the specific target proteins myeloperoxidase (MPO) and proteinase 3 (PR3). Understanding both layers is what turns a single line on a lab report into something clinically meaningful.

A negative result means no ANCAs were detected, and your symptoms are unlikely to be caused by ANCA-associated autoimmune vasculitis. A positive result means antibodies were found and a second test is usually run to identify exactly which protein they target. The pattern matters because c-ANCA usually maps to anti-PR3 and is most often seen in granulomatosis with polyangiitis, while p-ANCA usually maps to anti-MPO and is most often seen in microscopic polyangiitis or eosinophilic granulomatosis with polyangiitis.

What the antibody-level numbers mean

Many labs report ELISA results as concrete antibody concentrations in international units per milliliter. One commonly cited interpretation framework uses the following bands:

Values in the equivocal band are not definitive and often prompt repeat testing or careful clinical correlation. Reference cutoffs and units vary between laboratories, so always read your antibody level against the reference range printed on your specific report rather than memorising a single number.

Why “positive” is not the same as “diagnosis”

A positive ANCA on its own does not equal vasculitis. ANCAs have also been reported in 15% to 20% of people with systemic lupus erythematosus, particularly those with lupus nephritis, and positivity is higher in type 1 diabetes than in healthy individuals. That is why your clinician will read the antibody result alongside symptoms, urine findings, imaging, kidney function, and sometimes biopsy before settling on a diagnosis.

How ANCA testing works in the lab

ANCA testing is rarely a single assay. Labs typically combine two complementary methods to balance screening sensitivity with antigen specificity.

The first method is indirect immunofluorescence (IIF). A small amount of your blood is mixed with fixed neutrophils on a microscope slide. If ANCAs are present, they bind to the neutrophils, and a fluorescent stain reveals one of two patterns under the microscope — cytoplasmic staining (c-ANCA) or staining concentrated around the nucleus (p-ANCA). IIF gives a yes-or-no answer and tells the lab which broad pattern is present, but it does not tell you which protein the antibody is attacking.

The second method is enzyme-linked immunosorbent assay (ELISA). ELISA measures, in concrete units, how much antibody is binding to a specific antigen — usually MPO or PR3. This converts the qualitative IIF result into a quantitative one and pins down the target protein.

Reflex testing and why two methods are used together

Many labs run these two tests in a stepwise “reflex” sequence: IIF is performed first, and a positive screen automatically triggers ELISA on the same sample to identify the antigen and measure its level. The International Consensus Statement on Testing and Reporting ANCA endorses using both techniques in suspected patients, though the more specific antigen-based ELISA is increasingly used on its own.

Pattern–antigen pairing in healthy testing labs is usually consistent but not universal. c-ANCA is roughly 90% PR3-reactive and 10% MPO-reactive, while p-ANCA is about 90% MPO-reactive and 10% PR3-reactive. When the pattern and the ELISA target disagree, the laboratory and your clinician will treat the result with extra caution. Discordant findings are one reason ANCA reports include a comment recommending clinical correlation rather than a stand-alone diagnosis.

ANCA and inflammatory bowel disease

ANCA testing is not only used for vasculitis. It can also help sort out which form of inflammatory bowel disease (IBD) is most likely when symptoms — abdominal pain, chronic diarrhea, weight loss, blood in the stool — point toward IBD but the clinical picture is not yet clear.

In this setting, ANCA is interpreted alongside another antibody called ASCA (anti-Saccharomyces cerevisiae antibodies), which is more typical of Crohn’s disease. The combination is read as a pair:

If neither antibody is present, IBD is still possible — the antibody panel is supportive, not a rule-out test.

The ANCA seen in IBD is usually an “atypical” ANCA that has been associated with inflammatory bowel disease rather than vasculitis. That distinction matters: an atypical perinuclear pattern with negative MPO and PR3 ELISAs is far more suggestive of IBD or another non-vasculitic autoimmune process than of microscopic polyangiitis. If your symptoms point toward bowel disease rather than blood-vessel disease, your clinician may also order a calprotectin test and stool studies before recommending colonoscopy.

Conditions ANCA can point to beyond classic vasculitis

A positive ANCA result does not always mean granulomatosis with polyangiitis, microscopic polyangiitis, or eosinophilic granulomatosis with polyangiitis. Several other conditions can produce a positive result, and recognising them is part of how clinicians avoid over-diagnosing vasculitis.

Drug-induced ANCA

Some medications can trigger an ANCA-associated vasculitis that looks clinically like primary disease, sometimes with rapidly progressive kidney injury. A high MPO titer is common in this setting. Drugs most frequently linked to ANCA-associated vasculitis include:

• Hydralazine (used for blood pressure)
• Propylthiouracil and methimazole (used for hyperthyroidism)
• Allopurinol (used for gout)
• Sulfasalazine, minocycline, penicillamine, rifampicin, sofosbuvir, and anti-TNF-alpha biologics used in rheumatoid arthritis and ankylosing spondylitis
• Levamisole, a contaminant frequently found in cocaine, which can raise both anti-MPO and anti-PR3 antibodies along with skin lesions and joint pain

If your ANCA is positive and you take any of these medications, your clinician will look carefully at the timing and may pause the suspected agent.

Lupus, type 1 diabetes, and rheumatoid arthritis

Beyond drug-induced disease, ANCA positivity has been reported in 15% to 20% of people with systemic lupus erythematosus — particularly those with lupus nephritis — and is more common in type 1 diabetes than in healthy controls. Atypical ANCAs have also been described in rheumatoid arthritis. In these settings the ANCA is a finding to interpret alongside the broader autoimmune workup rather than a diagnosis in itself. An ANA test and rheumatoid factor are often ordered in parallel to clarify the underlying picture.

Monitoring vasculitis treatment and detecting relapse

Once ANCA-associated vasculitis has been diagnosed, the ANCA test does not disappear from your care. Many clinicians repeat ANCA testing during follow-up, both to track how the disease is responding to treatment and to watch for signs that it may be returning.

The reasoning is biologic. ANCA titers often fall when active inflammation is suppressed, and the reappearance of ANCA after a period of being negative has been linked to relapsing disease. The 2020 Central European Journal of Immunology review by FijoŁek and colleagues frames ANCA serology as a tool used for both classifying disease subsets and, more controversially, for monitoring.

The serial-measurement debate

There is genuine clinical disagreement about how reliable serial ANCA measurements are as a relapse predictor. The same review explicitly notes that “controversy exists regarding the utility of serial measurements of ANCA in patients with AAV to monitor treatment and predict disease relapse”. MedlinePlus echoes this caution, stating that ANCA “isn’t always an accurate way to measure how much disease you have”.

In practice this means:

• A rising ANCA titer is a signal to look more carefully at symptoms, urine, and kidney function — not, on its own, a reason to escalate treatment
• A persistently positive ANCA in someone who feels well is not automatically a relapse
• A negative ANCA on treatment does not guarantee the disease is fully quiet, since the test is not always an accurate gauge of disease burden

This is also why clinicians often pair ANCA monitoring with non-antibody markers of inflammation and organ function, such as CRP, ESR, creatinine, and urinalysis, each of which reflects a different facet of active small-vessel disease.

Frequently asked questions

What does an ANCA blood test check for?

An ANCA blood test looks for antibodies that mistakenly attack your own neutrophils, a type of white blood cell. It is mainly used to diagnose autoimmune vasculitis — conditions where small blood vessels become inflamed — and can also help distinguish ulcerative colitis from Crohn’s disease.

What is the difference between a c-ANCA and a p-ANCA test?

c-ANCA and p-ANCA describe two staining patterns seen under the microscope. c-ANCA stains throughout the cytoplasm of the neutrophil and usually reflects antibodies against PR3, while p-ANCA stains around the nucleus and usually reflects antibodies against MPO.

What is in an ANCA panel?

An ANCA panel typically combines an immunofluorescence screen, which reports c-ANCA or p-ANCA, with ELISA antigen tests that quantify antibodies against MPO and PR3. Some labs run them in a reflex sequence: ELISA only follows if the immunofluorescence screen is positive.

What does an ANCA titer mean on a lab report?

A titer is a way of reporting how much antibody is present in your sample. ANCA reports may include both an immunofluorescence titer and quantitative ELISA values in IU/mL. Monitoring titer changes over time has been described as useful for following the clinical course of disease, but cutoffs vary between labs, so the most reliable comparison is against your own lab’s reference range.

Can a positive ANCA mean something other than vasculitis?

Yes. ANCAs have been reported in 15% to 20% of people with systemic lupus erythematosus, more frequently in type 1 diabetes than in healthy individuals, and in inflammatory bowel disease and rheumatoid arthritis, often as an atypical p-ANCA. Certain medications, including hydralazine and propylthiouracil, can also cause a drug-induced ANCA-positive vasculitis.

Is ANCA used to monitor treatment?

Sometimes. Repeat ANCA testing is used during follow-up of ANCA-associated vasculitis, and a reappearance after treatment may signal relapse. However, the value of serial measurements is debated, and ANCA alone is not a precise gauge of how active the disease is.

Does diabetes affect ANCA results?

People with type 1 diabetes mellitus are more likely to have detectable ANCA than healthy individuals, though this does not mean they have vasculitis. The clinical meaning of a positive ANCA in someone with diabetes is interpreted in the context of symptoms and other findings.

When to talk to your doctor

ANCA testing is most useful when it is ordered because something specific has prompted it. If you have already had an ANCA test, the result is best discussed alongside your symptoms and other lab work rather than read in isolation. Reach out to your clinician — promptly, not at your next routine visit — if any of the following apply:

• Coughing up blood, persistent unexplained cough, or shortness of breath, which can reflect lung involvement in ANCA-associated vasculitis
• Blood in your urine, foamy urine, or new swelling in the legs, all of which can point to kidney inflammation requiring urgent evaluation
• Sudden changes in vision, hearing loss, ringing in the ears, or persistent sinus infections that do not respond to standard treatment
• New numbness, tingling, weakness, or shooting pains in the arms or legs, which may signal nerve involvement
• A positive ANCA result combined with general symptoms such as fatigue, fever, unexplained weight loss, joint aches, or skin rashes
• A rising ANCA titer during follow-up for known vasculitis, even if you feel well, so your clinician can review symptoms, urine, and kidney function before any treatment decision
• A new prescription for hydralazine, propylthiouracil, methimazole, allopurinol, minocycline, or another medication linked to drug-induced ANCA, especially if you develop new rashes, joint pain, or kidney symptoms shortly afterwards

A positive ANCA result alone is not a diagnosis, and a negative result does not rule out every form of vasculitis. Your clinician will weigh the antibody pattern, the antigen target, your symptoms, and additional tests — including imaging, urine studies, and sometimes a biopsy — before settling on next steps.

References

• MedlinePlus (U.S. National Library of Medicine, NIH)
• Cleveland Clinic
• Peer-reviewed reference
• PubMed (U.S. National Library of Medicine, NIH)

Last reviewed: 2026-05-17